Souhaitez-vous accéder aux communiqués récents ?

- Company intends to request a Type A meeting with FDA during the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter - - Key...

WEST CHESTER, Pa., Aug. 05, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...

– Leading pediatric dermatologist brings significant expertise in the treatment of skin diseases to help inform development of the Company’s product candidates – WEST CHESTER, Pa., July 23, 2020 ...

– Dr. Gary Goldenberg appointed Chief Medical Officer; Dr. Brad Catalone assumes the role of Head of Drug Development – – New leadership strengthens expertise in Clinical, Chemistry, Manufacturing,...

– Complete Response Letter Requests Additional Chemistry, Manufacturing, and Controls (CMC) and Human Factors Information – – No Clinical Safety or Efficacy Issues Identified – – Conference Call and...

WEST CHESTER, Pa., June 29, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...

- Pre-specified exploratory analysis showed VP-102 brought about a statistically significant percentage of patients with complete molluscum lesion clearance across all lesion count quartiles compared...

– Global biopharmaceutical industry veteran brings significant commercial expertise and business acumen to help advance the Company’s medical dermatology portfolio – WEST CHESTER, Penn., June ...

WEST CHESTER, Pa., May 27, 2020 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for viral skin diseases...

- Secured $55 million in non-dilutive loan facilities, of which $35 million was borrowed upon closing - - Continued to prepare for potential U.S. approval of VP-102 for the treatment of molluscum...